AXTA Axalta Coating Systems Ltd. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
AXTA Stock | Fundamental Analysis & Investment Insights
NYSE
Basic Materials
Specialty Chemicals
Current Price
Live
$33.62
Analyst Target
$36.71
+9.2%
Upside
52W High
$38.37
52W Low
$26.28
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$7.17B
P/E
16.32
ROE
21.3%
Profit margin
8.8%
Debt/Equity
1.46
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
AXTA's deterministic scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. The stock trades below the growth-based intrinsic value of $48.10 but above the conservative Graham Number of $22.25, suggesting mixed valuation signals. Despite solid profitability metrics like a 21.33% ROE and consistent earnings beats, revenue is contracting YoY by 2.40%, and insider activity is bearish with recent selling. Analysts recommend a 'buy' with a $36.71 target, implying moderate upside from current levels around $33.62.
Key Strengths
Strong return on equity (ROE) of 21.33%, well above sector average of -2.78%
Consistent earnings outperformance with 3 out of last 4 quarters beating estimates and an average surprise of 5.55%
Healthy operating margin of 15.76% in a competitive specialty chemicals environment
Forward P/E of 12.60 is significantly below sector average P/E of 33.54, suggesting relative value
Current ratio of 2.20 and quick ratio of 1.42 indicate solid short-term liquidity
Key Risks
Piotroski F-Score of 4/9 suggests below-average financial strength and limited resilience in downturns
Revenue growth is negative YoY (-2.40%), indicating top-line pressure despite earnings growth
High debt/equity ratio of 1.46, well above sector average of 0.63, increasing financial risk
Insider selling activity in the last 6 months signals lack of confidence from management
Missing key financial data (e.g., Altman Z-Score, EV/EBITDA, free cash flow) limits confidence in health assessment
AI Fair Value Estimate
Based on comprehensive analysis
$38.5
+14.5% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
58
Moderate
75
68
62
54
30
AI Verdict
Neutral with upside potential if execution improves
Key drivers: Below-average Piotroski score limiting health rating, Attractive forward valuation relative to peers, Earnings growth and beat rate support future outlook, High leverage and flat revenue cap upside
Confidence
70%
Value
75/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 12.60 is attractive vs sector average of 33.54
- Trading below intrinsic value of $48.10
Watchpoints
- Price above Graham Number ($22.25) by ~50%, reducing margin of safety
Future
68/100
Ref Growth rates
Positives
- Earnings growth of 10.90% YoY and 8.90% Q/Q
- Analyst target implies 9.2% upside
Watchpoints
- Revenue growth is negative (-2.40% YoY)
- PEG ratio unavailable due to uncertainty in growth sustainability
Past
62/100
Ref Historical trends
Positives
- Long history of earnings beat frequency (21 out of 25 quarters beat or met)
Watchpoints
- Recent 1Y price return of -8.8% underperforms sector momentum
- Revenue growth has been inconsistent over recent quarters
Health
54/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current and quick ratios indicate adequate liquidity
Watchpoints
- Piotroski F-Score of 4/9 indicates weak financial health
- Debt/Equity of 1.46 is high vs sector average of 0.63
- No Altman Z-Score available for distress risk analysis
Dividend
30/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength score of 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$33.62
Analyst Target
$36.71
Upside/Downside
+9.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AXTA and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AXTA
Axalta Coating Systems Ltd.
Primary
|
+21.2% | +22.1% | -8.8% | +13.8% | +4.1% | +0.1% |
|
AUGO
Aura Minerals Inc.
Peer
|
+185.0% | +185.0% | +185.0% | +173.8% | +31.9% | +13.4% |
|
BCPC
Balchem Corporation
Peer
|
+45.9% | +30.9% | +3.9% | +13.3% | +6.7% | -0.7% |
|
ALM
Almonty Industries Inc.
Peer
|
+830.3% | +1788.7% | +749.0% | +341.1% | +38.8% | +5.1% |
|
BVN
Compañía de Minas Buenaventura S.A.A.
Peer
|
+275.8% | +350.4% | +194.5% | +113.6% | +25.7% | +7.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
16.32
Forward P/E
12.6
PEG Ratio
N/A
P/B Ratio
3.15
P/S Ratio
1.39
EV/Revenue
1.94
EV/EBITDA
9.89
Market Cap
$7.17B
Profitability
Profit margins and return metrics
Profit Margin
8.81%
Operating Margin
15.76%
Gross Margin
34.59%
ROE
21.33%
ROA
6.44%
Growth
Revenue and earnings growth rates
Revenue Growth
-2.4%
Earnings Growth
+10.9%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+8.9%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.46
Moderate
Current Ratio
2.2
Strong
Quick Ratio
1.42
Good
Cash/Share
$2.84
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-10
$N/A
2025-10-28
$0.67
+4.2% surprise
2025-07-30
$0.64
+4.4% surprise
2025-05-07
$0.59
+8.1% surprise
Basic Materials Sector Comparison
Comparing AXTA against 41 companies in the Basic Materials sector
(1 bullish, 21 neutral, 19 bearish)
P/E Ratio
16.32
This Stock
vs
30.38
Sector Avg
-46.3%
(Discount)
Return on Equity (ROE)
21.33%
This Stock
vs
0.39%
Sector Avg
+5304.3%
(Excellent)
Profit Margin
8.81%
This Stock
vs
-2.41%
Sector Avg
-465.6%
(Weaker)
Debt to Equity
1.46
This Stock
vs
0.61
Sector Avg
+141.6%
(Higher)
Revenue Growth
-2.4%
This Stock
vs
15.82%
Sector Avg
-115.2%
(Slower)
Current Ratio
2.2
This Stock
vs
2.28
Sector Avg
-3.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AXTA
Axalta Coating Systems Ltd.
|
NEUTRAL | $7.17B | 16.32 | 21.3% | 8.8% | $33.62 | |
|
AUGO
Aura Minerals Inc.
|
BEARISH | $5.71B | - | -15.5% | -5.6% | $68.3 | |
|
BCPC
Balchem Corporation
|
NEUTRAL | $5.44B | 36.74 | 12.1% | 14.7% | $167.54 | |
|
ALM
Almonty Industries Inc.
|
BEARISH | $5.05B | - | -57.3% | -216.3% | $19.68 | |
|
BVN
Compañía de Minas...
|
NEUTRAL | $9.42B | 20.73 | 12.3% | 30.7% | $37.1 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-23 | TUFANO AMY | Officer | Stock Award | 9,476 | - |
| 2025-12-23 | TABLIN-WOLF ALEX J.D. | General Counsel | Stock Award | 10,496 | - |
| 2025-12-22 | WEAVER TROY D | Officer | Option Exercise | 11,006 | $255,779 |
| 2025-09-19 | TUFANO AMY | Officer | Stock Award | 3,657 | - |
| 2025-09-19 | TABLIN-WOLF ALEX J.D. | General Counsel | Stock Award | 4,877 | - |
| 2025-08-19 | TUFANO AMY | Officer | Sale | 3,194 | $99,206 |
| 2025-08-14 | ANDERSON CARL DOUGLAS II | Chief Financial Officer | Stock Award | 20,656 | - |
| 2025-08-01 | MASSEY ANTHONY | Officer | Stock Award | 2,070 | - |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
14 analysts
Seaport Global
2026-01-23
Buy
Neutral
UBS
2026-01-12
Buy
Neutral
Baird
2026-01-07
Outperform
Neutral
Citigroup
2025-12-18
Buy
Buy
RBC Capital
2025-11-19
Outperform
Sector Perform
JP Morgan
2025-10-30
Neutral
Neutral
Citigroup
2025-10-29
Buy
Buy
UBS
2025-10-29
Buy
Buy
RBC Capital
2025-10-29
Outperform
Outperform
Wells Fargo
2025-10-29
Overweight
Overweight
Past News Coverage
Recent headlines mentioning AXTA from our newsroom.
Newest → oldest
No matching news yet.